trial · primary record
PRGN-2012
Respiratory Recurrent Papillomatosis (RRP)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 50 |
| Primary completion | 2030-07-01 |
| Primary endpoint | To determine the complete response rate, defined as the percentage of participants who do not require an intervention (either medical or surgical) in the 12 months following completion of treatment with combination systemic bevacizumab and PRGN-... |
| Registry ID | NCT07756840 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:35.845Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07756840
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.